DocWire News Editors

DocwireNews

Dapagliflozin is an effective treatment for patients with heart failure with reduced ejection fraction (HFrEF) across all age groups, according to the findings of a study presented at the American Heart Association 2019 Scientific Sessions in Philadelphia.&ldquo;Patients with HFrEF are often elderly and more likely to have comorbidities such as renal disease, which may limit the use of pharmacological therapies,&rdquo; the research authors wrote in their abstract. &ldquo;Therefore, we assessed the efficacy and safety of dapagliflozin according to age in DAPA-HF.&rdquo;The researchers enrolled 4,774 (mean age, 66, 23% female) patients from 410 centers across 20 countries between February 15, 2017 and August 17, 2018. The population of interest were considered eligible for enrollment if they were a New York Heart Association (NYHA) class II-IV, with a left ventricular ejection fraction (LVEF) of 40% or less; N-terminal (NT)-pro hormone BNP (NT-prBNP) of 600 pg/mL or greater; and on standard drug or device therapy for HF. &nbsp;Subjects were administered either 10 mg once daily of dapagliflozin or a matching placebo. The researchers assessed several outcomes, including all-cause and cardiovascular (CV) death and recurrent hospitalizations.According to the study results, dapagliflozin attenuated the risk of worsening HF events and CV death and improved symptoms in patients with HFrEF when used in conjunction with standard therapy. The researchers noted that benefits were consistent across all age groups evaluated in the study. The relative and absolute risk reductions in death and hospitalization were substantial and clinically relevant. The absolute benefits in older patients were large because they were at higher risk than younger patients. Dapagliflozin was found to be well-tolerated, and the rate of treatment discontinuation was low across all age groups.&ldquo;Dapagliflozin offers a new approach to the treatment of HFrEF, irrespective of age,&rdquo; Dr. Felipe Martinez, of Cordoba National University, noted in a presentation of the study results.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Dapagliflozin Effective Across All Age Groups: DAPA-HF Analysis

AHA 2019

Dapagliflozin is an effective treatment for patients with heart failure with reduced ejection fraction (HFrEF) across all age groups, according to the findings of a study ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe